IDYA vs. JANX, XENE, ARWR, FOLD, HCM, PBH, RARE, MRUS, ACAD, and MLTX
Should you be buying IDEAYA Biosciences stock or one of its competitors? The main competitors of IDEAYA Biosciences include Janux Therapeutics (JANX), Xenon Pharmaceuticals (XENE), Arrowhead Pharmaceuticals (ARWR), Amicus Therapeutics (FOLD), HUTCHMED (HCM), Prestige Consumer Healthcare (PBH), Ultragenyx Pharmaceutical (RARE), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical preparations" industry.
IDEAYA Biosciences (NASDAQ:IDYA) and Janux Therapeutics (NASDAQ:JANX) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, community ranking, profitability and risk.
IDEAYA Biosciences received 91 more outperform votes than Janux Therapeutics when rated by MarketBeat users. Likewise, 67.86% of users gave IDEAYA Biosciences an outperform vote while only 62.16% of users gave Janux Therapeutics an outperform vote.
IDEAYA Biosciences has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 3.87, indicating that its share price is 287% more volatile than the S&P 500.
IDEAYA Biosciences has a net margin of -483.05% compared to Janux Therapeutics' net margin of -762.92%. Janux Therapeutics' return on equity of -13.49% beat IDEAYA Biosciences' return on equity.
Janux Therapeutics has lower revenue, but higher earnings than IDEAYA Biosciences. Janux Therapeutics is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.
IDEAYA Biosciences currently has a consensus price target of $46.80, suggesting a potential upside of 12.88%. Janux Therapeutics has a consensus price target of $69.50, suggesting a potential upside of 41.72%. Given Janux Therapeutics' higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than IDEAYA Biosciences.
98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 3.5% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 35.4% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, IDEAYA Biosciences had 3 more articles in the media than Janux Therapeutics. MarketBeat recorded 28 mentions for IDEAYA Biosciences and 25 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.37 beat IDEAYA Biosciences' score of 0.24 indicating that Janux Therapeutics is being referred to more favorably in the news media.
Summary
Janux Therapeutics beats IDEAYA Biosciences on 9 of the 17 factors compared between the two stocks.
Get IDEAYA Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IDEAYA Biosciences Competitors List
Related Companies and Tools
